VRTX
Vertex Pharmaceuticals Inc
503.50$
-0.2%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -81.5% | +456.9% | -387.3% | – | -57.3% | +40.1% | +31.0% | +15.7% | -59.9% | +186.8% | -21.2% | – | |
| – | +40.1% | -9.3% | +0.9% | -1.5% | -12.6% | +4.1% | +6.8% | +4.4% | +3.1% | +0.4% | +1.1% | – | |
| – | +59.4% | -8.0% | -19.6% | +19.7% | -9.1% | -1.0% | +0.7% | +16.5% | -19.1% | +5.6% | +2.3% | – | |
| – | -544.1% | – | -286.7% | – | -455.7% | – | – | – | -733.6% | – | -147.0% | – | |
| – | +43.1% | +327.5% | -69.1% | -11.7% | +36.8% | -56.0% | +258.0% | -30.1% | +46.8% | -10.7% | -15.9% | – | |
| – | +653.2% | +141.0% | -78.3% | -25.0% | +136.2% | -93.2% | +768.3% | -75.9% | +146.2% | +49.9% | -89.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +27.8% | -12.2% | +144.1% | -3.9% | +35.8% | +2.0% | -8.0% | +173.4% | -87.8% | +331.9% | -16.2% | – | |
| – | – | – | – | – | -75.9% | +0.0% | +0.0% | +7.7% | +0.0% | – | – | – | |
| – | -27.4% | +198.4% | +0.3% | +8.1% | +1.0% | +73.9% | -48.7% | +230.6% | -93.3% | +597.9% | -20.8% | – | |
| – | -177.3% | – | – | – | -202.9% | – | +162.0% | -111.5% | – | +197.9% | +55.6% | – | |
| – | -85.6% | +499.5% | -462.0% | – | -62.2% | +58.2% | +19.2% | +22.9% | -69.4% | +271.4% | -21.7% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.